


Recombinant Cynomolgus Monkey HGFR/c-MET His-tag

Catalog Number: 11390-ME

DESCRIPTION	
Source	Human embryonic kidney cell, HEK293-derived cynomolgus monkey HGFR/c-MET protein Alpha Chain Glu25-Arg307 & Beta Chain Ser308-Thr932 Accession # EHH52447.1
N-terminal Sequence Analysis	Glu25 & Ser308
Predicted Molecular Mass	33 kDa & 70 kDa

SPECIFICATIONS	
SDS-PAGE	41-46 kDa (alpha chain) & 76-84 kDa (beta chain) under reducing conditions.
Activity	Measured by its binding ability in a functional ELISA. Recombinant Cynomolgus Monkey HGFR/c-MET His-tag (Catalog # 11390-ME) binds to Recombinant Human HGF (NS0-expressed) Protein (Catalog # 294-HGN) with a ED ₅₀ of <0.400 μg/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE	
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.





Recombinant Cynomolgus Monkey HGFR/c-MET His-tag

Catalog Number: 11390-ME

BACKGROUND

HGF R, also known as Met (from *N*-methyl-*N*-nitro-*N*-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. Based on the high homology (98%) between cynomolgus and human HGF R, cynomolgus HGF R is predicted to be synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular α chain and a 145 kDa transmembrane β chain (1, 2). The extracellular domain (ECD) contains a seven bladed β -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternative splicing generate additional forms of human HGF R which either lack of the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the α and β chains (5-7). The sema domain, which is formed by both the α and β chains of HGF R, mediates both ligand binding and receptor dimerization (3, 7). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (8, 9). HGF stimulation induces HGF R down-regulation v internalization and proteasome-dependent degradation (10). In the absence of ligand, HGF R forms noncovalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin α 6/ β 4, Plexins B1, 2, 3, and MSP R/Ron (11-18). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (11 - 18). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (11, 15, 16). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neigh

References

- 1. Birchmeier, C. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:915.
- 2. Grzelakowska-Sztabert, B. and M. Dudkowska (2011) Growth Factors 29:105.
- 3. Gherardi, E. et al. (2003) Proc. Natl. Acad. Sci. 100:12039.
- 4. Park, M. et al. (1987) Proc. Natl. Acad. Sci. 84:6379.
- 5. Crepaldi, T. et al. (1994) J. Biol. Chem. 269:1750.
- 6. Prat, M. et al. (1991) Mol. Cell. Biol. 12:5954.
- 7. Rodrigues, G.A. et al. (1991) Mol. Cell. Biol. 11:2962.
- 8. Kong-Beltran, M. et al. (2004) Cancer Cell 6:75.
- 9. Naldini, L. et al. (1991) Mol. Cell. Biol. 11:1793.
- 10. Ponzetto, C. et al. (1994) Cell 77:261.
- 11. Jeffers, M. et al. (1997) Mol. Cell. Biol. 17:799.
- 12. Orian-Rousseau, V. et al. (2002) Genes Dev. 16:3074.
- 13. Klosek, S.K. et al. (2005) Biochem. Biophys. Res. Commun. 336:408.
- 14. Jo, M. et al. (2000) J. Biol. Chem. 275:8806.
- 15. Wang, X. et al. (2002) Mol. Cell 9:411.
- 16. Trusolino, L. et al. (2001) Cell 107:643.
- 17. Giordano, S. et al. (2002) Nat. Cell Biol. 4:720.
- 18. Conrotto, P. et al. (2004) Oncogene 23:5131.
- 19. Follenzi, A. et al. (2000) Oncogene 19:3041.
- 20. Sonnenberg, E. et al. (1993) J. Cell Biol. 123:223.